Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL27649777 | 1.00 | LCK (0.48) | LCKFYNDAOCES2CES1 | |
| SCHEMBL27445546 | 0.86 | LCK (0.41) | LCKFYNDAOCES2CES1 | |
| SCHEMBL129324 | 0.84 | — | — | |
| SCHEMBL29575307 | 0.82 | — | — | |
| SCHEMBL28199189 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL1031787 | 0.82 | — | — | |
| Phosphoric Acid SCHEMBL1094050 | 0.81 | CES2 (0.39) | LCKFYNDAOCES2CES1 | |
| Phosphonic Acid SCHEMBL27762789 | 0.81 | CES2 (0.39) | LCKFYNDAOCES2CES1 | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL28410835 | 0.76 | SMN1; SMN2 (0.42) | LCKFYNDAOCES2CES1 | |
| Propane SCHEMBL6193423 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974833-B | Preparation method of 3-aminothiophene oxalate | 苏州汉德创宏生化科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-115974833-A | Preparation method of 3-aminothiophene oxalate | 苏州汉德创宏生化科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-111072930-B | Fluorine-containing thiophene derivative polymer film PEDOT-F, and preparation method and application thereof | 浙江工业大学 | 2022-05-24 | — | — | CN | claimed |
| CN-111072930-A | Fluorine-containing thiophene derivative polymer film PEDOT-F, and preparation method and application thereof | 浙江工业大学 | 2020-04-28 | — | — | CN | claimed |
| CN-111018828-A | Fluorine-containing thiophene derivative 3- (N-trifluoroacetylamino) thiophene and synthetic method and application thereof | 浙江工业大学 | 2020-04-17 | — | — | CN | claimed |
| CN-108727414-A | A kind of unsubstituted thiophene bioxindol class compounds of N- and preparation method thereof | 中国科学院青岛生物能源与过程研究所 | 2018-11-02 | — | — | CN | claimed |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119161353-A | Design, synthesis and activity evaluation of pyranopyrimidine heterocyclic p97/VCP inhibitors | 首都医科大学 | 2024-12-20 | — | — | CN | disclosed |
| CN-115974833-B | Preparation method of 3-aminothiophene oxalate | 苏州汉德创宏生化科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-115974833-B | Preparation method of 3-aminothiophene oxalate | 苏州汉德创宏生化科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-115974833-B | Preparation method of 3-aminothiophene oxalate | 苏州汉德创宏生化科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6331639-B2 | BY REACTING A 3-((ALKYL, ALKOXY, PHENYL OR HETEROARYL)CARBONYLAMINO)THIOPHENE WITH A KETONE IN THE PRESENCE OF AN ACID AND REDUCING THE REACTION MIXTURE; AGRICULTURAL FUNGICIDES | MITSUI CHEMICALS, INC. (JP) | 2001-12-18 | — | — | US | disclosed |
| US-20010023295-A1 | Process for preparing 2-alkyl-3-aminothiophene derivative and 3-aminothiophene derivative | KATSUTA HIROYUKI (JP) | 2001-09-20 | — | — | US | disclosed |
| US-6239282-B1 | ALKYLATING THE CORRESPONDING 3-AMIDOTHIOPHENE COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023295-A1 | Process for preparing 2-alkyl-3-aminothiophene derivative and 3-aminothiophene derivative | SULT1E1, CYP4B1, CYP3A4 | LCK 3145/4885FYN 2289/4885DAO 37/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | LCK 1455/4885FYN 1649/4885DAO 659/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | LCK 3015/4885FYN 2637/4885DAO 1489/4885 |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | LCK 43/4885FYN 30/4885DAO 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.